ORIC Pharmaceuticals Bundle
Who Really Owns ORIC Pharmaceuticals?
Uncover the intricate web of ownership that shapes the future of ORIC Pharmaceuticals, a pioneering force in the biopharmaceutical industry. From its inception to its current status as a publicly traded entity, ORIC's ownership structure has undergone significant transformations. Understanding the dynamics of ORIC ownership is crucial for anyone seeking to navigate the complexities of the biotech market. This exploration delves into the key players and pivotal moments that have defined ORIC's journey.
As a publicly traded company since its IPO in April 2020, ORIC Pharmaceuticals' stock performance and strategic decisions are heavily influenced by its diverse shareholder base. The company's mission, 'Overcoming Resistance In Cancer,' drives its focus on innovative cancer treatments. To gain a deeper understanding of ORIC's strategic direction, consider exploring the ORIC Pharmaceuticals SWOT Analysis, which highlights key strengths and weaknesses. Analyzing ORIC Pharmaceuticals' financial reports and understanding its market capitalization are vital steps for investors.
Who Founded ORIC Pharmaceuticals?
In 2014, ORIC Pharmaceuticals was established with the goal of addressing cancer resistance. The company's foundation was built upon the expertise of three key individuals: Dr. Charles L. Sawyers, Dr. Richard A. Heyman, and Dr. Scott W. Lowe.
These founders brought substantial experience in cancer research and drug development to ORIC. Dr. Sawyers is notable for his contributions to cancer therapies, while Dr. Heyman has a track record of co-founding successful pharmaceutical companies. Dr. Lowe is an expert in tumor networks.
Initially, ORIC Pharmaceuticals operated as a privately held, clinical-stage oncology company. While specific initial equity details are not publicly available, it is known that all founders held equity in the company. The early financial backing for ORIC came from prominent biotechnology investors, which helped shape the company's initial trajectory.
Founding Team
The founders of ORIC Pharmaceuticals, Dr. Charles L. Sawyers, Dr. Richard A. Heyman, and Dr. Scott W. Lowe, brought extensive experience in cancer research and drug development.
Early Investors
Early funding for ORIC came from leading biotechnology investors, including The Column Group, OrbiMed Advisors, and Fidelity Management & Research Company.
Equity and Compensation
All founders were equity holders. Drs. Sawyers and Lowe also served as scientific advisors, and Dr. Heyman served on the board, receiving compensation.
Company Stage
At its inception, ORIC Pharmaceuticals was a privately held, clinical-stage oncology company.
Leadership Roles
Dr. Heyman served on the board since March 2015 and as Chairman since May 2018.
Focus
ORIC Pharmaceuticals was founded to combat cancer resistance.
Ownership and Investment Insights
Understanding the early ownership structure of ORIC Pharmaceuticals provides insights into its strategic direction and financial backing. The initial investors played a crucial role in supporting the company's research and development. For more details on the company's growth strategy, you can refer to the Growth Strategy of ORIC Pharmaceuticals article.
- The founders' expertise was a key asset in securing early investment.
- The involvement of experienced board members, such as Dr. Heyman, helped guide the company.
- Early funding rounds from notable investors helped ORIC advance its clinical programs.
- ORIC's focus on oncology and its initial private status shaped its early development.
ORIC Pharmaceuticals SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has ORIC Pharmaceuticals’s Ownership Changed Over Time?
The evolution of ORIC Pharmaceuticals' ownership structure is marked by its transition from a private to a public entity. The company's Initial Public Offering (IPO) on April 24, 2020, was a pivotal moment. The IPO involved the offering of 7,500,000 shares of common stock at $16.00 per share, raising $120.0 million in gross proceeds. This was followed by the underwriters' option to purchase an additional 1,125,000 shares, increasing the total gross proceeds to $138.0 million.
As of June 2025, ORIC Pharmaceuticals (NASDAQ: ORIC) has a market capitalization of roughly $824 million. The shift to a publicly traded status broadened its investor base, which increased scrutiny from public markets and required greater transparency through SEC filings, impacting the company's strategic direction.
| Shareholder | Percentage of Shares (as of March 30, 2025) | Shares Held |
|---|---|---|
| Viking Global Investors LP | 9.25% | Data not available |
| BlackRock, Inc. | 7.65% | Data not available |
| Pfizer Inc | 7.56% | Data not available |
The ownership of ORIC Pharmaceuticals is largely institutional, with 325 institutional owners and shareholders holding a total of 93,163,864 shares. Key institutional investors include Viking Global Investors Lp, BlackRock, Inc., Pfizer Inc, Nextech Invest, Ltd., Nextech Invest AG, Alkeon Capital Management Llc, Column Group LLC, EcoR1 Capital, LLC, Vanguard Group Inc, and VR Adviser, LLC. In May 2025, institutional investors' holdings remained at 113.96%, while mutual funds increased their holdings from 35.04% to 35.14%.
Key Takeaways on ORIC Ownership
ORIC Pharmaceuticals transitioned from a private to a publicly traded company through an IPO in April 2020. The company's ownership structure is primarily institutional, with several major investors holding significant stakes.
- The IPO raised a total of $138.0 million in gross proceeds.
- Institutional investors hold a significant portion of ORIC stock.
- The shift to a public company has increased market scrutiny.
- For more detailed information, you can check out this article about ORIC Pharmaceuticals.
ORIC Pharmaceuticals PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on ORIC Pharmaceuticals’s Board?
The current Board of Directors at ORIC Pharmaceuticals, as of June 2025, includes individuals with extensive experience in oncology and drug development. The board is composed of Jacob Chacko, M.D. (President and Chief Executive Officer), Richard Heyman, Ph.D. (Chairman, Co-Founder, Scientific Advisory Board), Mardi C. Dier (Board Member and CFO of Madrigal Pharmaceuticals), Steve L. Hoerter (Board Member and President & CEO of Deciphera Pharmaceuticals), Lori Kunkel, M.D. (Board Member), and Angie You, Ph.D. (Board Member and CEO of Architect Therapeutics). Dr. Heyman, a co-founder, represents the founding ownership on the board and has served as Chairman since May 2018.
This composition reflects a blend of scientific expertise and leadership experience, crucial for guiding a biotech company. The board's structure and the expertise of its members are key factors in understanding the dynamics of ORIC ownership and the direction of the ORIC stock. Understanding who the key decision-makers are provides insights into the company's strategic direction and operational oversight. The presence of both founders and experienced industry leaders suggests a balance between innovation and established business practices within the company.
| Board Member | Title | Affiliation |
|---|---|---|
| Jacob Chacko, M.D. | President and Chief Executive Officer | |
| Richard Heyman, Ph.D. | Chairman, Co-Founder, Scientific Advisory Board | |
| Mardi C. Dier | Board Member | CFO of Madrigal Pharmaceuticals |
| Steve L. Hoerter | Board Member | President & CEO of Deciphera Pharmaceuticals |
| Lori Kunkel, M.D. | Board Member | |
| Angie You, Ph.D. | Board Member | CEO of Architect Therapeutics |
The voting structure of ORIC Pharmaceuticals typically operates on a one-share-one-vote basis, which is standard for publicly traded companies on the Nasdaq Global Select Market. There are no public indications of special voting rights or golden shares that would grant outsized control to specific individuals or entities beyond their proportional shareholding. Recent SEC filings, such as those in June 2025, show regular statements of changes in beneficial ownership by company insiders. For example, insider selling has been observed in the past six months, with executives like Jacob Chacko (President and CEO), Dominic Piscitelli (CFO), and Pratik S. Multani (Chief Medical Officer) selling shares. These transactions are part of the typical activities of publicly traded companies and reflect individual financial planning rather than governance controversies.
Understanding ORIC Pharmaceuticals Ownership
The board of directors at ORIC Pharmaceuticals includes experienced professionals in oncology and drug development. This structure, along with the standard one-share-one-vote system, provides insights into the ORIC ownership and ORIC stock dynamics.
- The board includes a mix of scientific and business leadership.
- Voting is typically based on one share, one vote.
- Insider transactions are regularly reported.
- For further insights, explore the Revenue Streams & Business Model of ORIC Pharmaceuticals.
ORIC Pharmaceuticals Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped ORIC Pharmaceuticals’s Ownership Landscape?
Recent developments in the ownership profile of ORIC Pharmaceuticals include a significant private placement financing in May 2025. This strategic move involved a $125 million capital raise, priced at an 18% premium, led by SR One, the life sciences investment arm of Roche. Key investors such as Point72, Viking Global, and Venrock Healthcare also participated. This financing is expected to extend the company's financial runway into late 2027, allowing ORIC Pharmaceuticals to advance its lead asset, ORIC-944, through a pivotal Phase 3 readout without immediate dilution risks. The company's focus on advancing its clinical programs has been a key driver for investor confidence.
Industry trends show a strong presence of institutional investors in ORIC. As of June 2025, institutional investors hold 95.05% of the stock. While there have been insider sales by executives, these are common in public companies. ORIC Pharmaceuticals has also engaged in strategic collaborations with major pharmaceutical companies to advance its clinical programs, which can indirectly influence ownership by enhancing investor confidence. For more insights, you can read the Brief History of ORIC Pharmaceuticals.
The company's leadership team has been expanded, with the appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs in August 2024, preparing for potential registrational trials in 2025. These strategic moves and the high institutional ownership percentage highlight the confidence in ORIC's future and its potential in the biotech sector. The company's ability to secure funding and form partnerships underscores its position within the competitive landscape of publicly traded companies.
Key Shareholders
Major institutional investors include SR One, Point72, Viking Global, and Venrock Healthcare. These investors, along with others, hold a significant portion of ORIC Pharmaceuticals stock, reflecting confidence in the company's strategic direction and potential for growth. This indicates a strong institutional backing for ORIC.
Strategic Partnerships
ORIC Pharmaceuticals has formed partnerships with major pharmaceutical companies such as Pfizer, Bayer, and Johnson & Johnson. These collaborations are crucial for advancing clinical programs like ORIC-114 and ORIC-944. These partnerships may indirectly influence ownership by bolstering investor confidence and attracting further investment.
Ownership Structure
The ownership structure of ORIC Pharmaceuticals is heavily influenced by institutional investors, who hold approximately 95.05% of the company's stock as of June 2025. This high percentage indicates a strong institutional interest in the company and its prospects. The company's focus on advancing its clinical programs has been a key driver for investor confidence.
Financial Strategy
The $125 million private placement in May 2025 is a key financial maneuver. This strategic capital raise, priced at an 18% premium, is designed to extend the company's cash runway. This financial strategy allows ORIC to fund its operations and advance its clinical trials without immediate dilution risks, which is crucial for long-term growth.
ORIC Pharmaceuticals Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of ORIC Pharmaceuticals Company?
- What is Competitive Landscape of ORIC Pharmaceuticals Company?
- What is Growth Strategy and Future Prospects of ORIC Pharmaceuticals Company?
- How Does ORIC Pharmaceuticals Company Work?
- What is Sales and Marketing Strategy of ORIC Pharmaceuticals Company?
- What is Brief History of ORIC Pharmaceuticals Company?
- What is Customer Demographics and Target Market of ORIC Pharmaceuticals Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.